You are here

  • Home
  • Archive
  • Volume 11, Issue 9
  • Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

 

Online download statistics by month:

Online download statistics by month: September 2023 to August 2025

AbstractFullPdf
Sep 2023419420125
Oct 202319018990
Nov 202311611649
Dec 202310911073
Jan 2024767749
Feb 2024707039
Mar 2024575760
Apr 2024616157
May 2024484841
Jun 2024585741
Jul 2024626432
Aug 2024374025
Sep 2024596034
Oct 2024474737
Nov 2024505139
Dec 2024666734
Jan 2025535327
Feb 2025909028
Mar 2025838362
Apr 2025787840
May 2025646439
Jun 2025444526
Jul 2025110
Aug 2025110
Total193919491047